Press Releases

06.03.2017

Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer

05.31.2017

Pfizer Announces Acceptance of Regulatory Submissions by U.S. FDA and European Medicines Agency for SUTENT® (sunitinib) for Adjuvant Treatment of Adult Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery

05.30.2017

European Commission Approves Pfizer’s TRUMENBA® to Help Prevent Meningococcal Group B Disease in Adolescents and Adults

05.25.2017

FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications

05.24.2017

Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Corporation

05.22.2017

Pharma Completes Patient Recruitment Of Recombinant Human Alkaline Phosphatase (Recap) Phase II Trial In Acute Kidney Injury

05.17.2017

Pfizer Oncology to Present Data Across 13 Different Types of Cancer at ASCO 2017 Annual Meeting

05.17.2017

Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data Highlighting Potential of Avelumab in Challenging Cancers at ASCO 2017

05.17.2017

Pfizer Invites Public to View and Listen to Webcast of June 9 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations

05.16.2017

Sangamo Receives Fast Track Designation From The Fda For Sb-525 Investigational Hemophilia A Gene Therapy

05.16.2017

Sangamo Receives Fast Track Designation From The Fda For Sb-525 Investigational Hemophilia A Gene Therapy

05.12.2017

TNO Starts Research Initiative With Industrial Partners To Combat Obesity-Associated Liver Disease